(0.17%) 5 140.25 points
(0.09%) 38 476 points
(0.28%) 17 896 points
(-0.02%) $83.83
(1.14%) $1.945
(0.22%) $2 352.30
(0.54%) $27.69
(1.98%) $940.40
(-0.20%) $0.933
(-0.27%) $11.00
(-0.33%) $0.798
(1.27%) $93.04
@ $11.29
発行日: 14 2月 2024 @ 05:33
リターン: -11.34%
前回のシグナル: 2月 13 - 23:30
前回のシグナル:
リターン: 2.98 %
Live Chart Being Loaded With Signals
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States...
Stats | |
---|---|
本日の出来高 | 290 462 |
平均出来高 | 430 561 |
時価総額 | 1.03B |
EPS | $0 ( 2024-03-19 ) |
次の収益日 | ( $-0.740 ) 2024-05-21 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -7.82 |
ATR14 | $0.00800 (0.08%) |
ボリューム 相関
Immatics N.V. 相関
10 最も負の相関 | |
---|---|
MLCO | -0.927 |
EZGO | -0.926 |
RXDX | -0.925 |
FWONK | -0.922 |
BRAC | -0.92 |
LUNA | -0.918 |
HWCC | -0.917 |
BKNG | -0.917 |
MLVF | -0.916 |
MOMO | -0.915 |
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
Immatics N.V. 相関 - 通貨/商品
Immatics N.V. 財務諸表
Annual | 2023 |
収益: | $54.00M |
総利益: | $-64.67M (-119.76 %) |
EPS: | $-1.200 |
FY | 2023 |
収益: | $54.00M |
総利益: | $-64.67M (-119.76 %) |
EPS: | $-1.200 |
FY | 2022 |
収益: | $172.83M |
総利益: | $66.05M (38.22 %) |
EPS: | $0.550 |
Financial Reports:
No articles found.
Immatics N.V.
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its ACTengine product candidates are in Phase I clinical trials, which include IMA201 that targets melanoma-associated antigen 4 or 8 in patients with solid tumors; IMA202 that targets melanoma-associated antigen 1 in patients with various solid tumors, including squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203 that targets preferentially expressed antigen in melanoma in adult patients with relapsed and/or refractory solid tumors, as well as IMA204, which is in preclinical studies that targets tumor stroma cell. The company's TCR Bispecifics product candidates, which are in preclinical studies include IMA401, a cancer testis antigen for the treatment of solid tumors; and IMA402 for the treatment of solid tumors. It also develops IMA101 for the treatment of cancer; and IMA301, an allogenic cellular therapy product candidate. The company has a strategic collaboration agreement with GlaxoSmithKline Intellectual Property Development Limited to develop novel adoptive cell therapies targeting multiple cancer indications; MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。